Dutch to reimburse Exogen's ultrasound:
This article was originally published in Clinica
The Dutch government has approved the reimbursement of Exogen's ultrasound therapy from April 1, for use on non-healing bone fractures of longer than six months. This is the first ultrasound therapy to win reimbursement approval in Europe. Piscataway, New Jersey-based Exogen's low-intensity, non-invasive treatment is already reimbursed in the US, where it is marketed by Smith & Nephew, and in Japan, where it was launched by Teijin.
You may also be interested in...
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.